News + Events
9th Annual Sachs Neuroscience Innovation Forum
San Francisco, CA
11 January 2026
Klaus Dugi, CEO – Attending
View event website
Press Releases
- Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease 2 December 2025
- Vandria announces first subjects dosed in its first-in-human Phase 1 clinical trial of VNA-318 brain-penetrant mitophagy inducer 18 December 2024
- Hevolution Foundation and Dolby Family Ventures join Vandria’s 2nd Series A closing, bringing the total round to $30.7M (CHF 28.3M) to Progress the Mitophagy Inducer VNA-318 into CNS Clinical Development 21 August 2024
- Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle 8 February 2024
- Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform 14 December 2023
Events
Biotech Showcase, 2026
San Francisco, CA
12-14 January 2026
Klaus Dugi, CEO and
Peter Harboe-Schmidt, Head BD & Finance – Attending
View event website
Past Events
